230 related articles for article (PubMed ID: 29945920)
1. Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus.
Schafer PH; Ye Y; Wu L; Kosek J; Ringheim G; Yang Z; Liu L; Thomas M; Palmisano M; Chopra R
Ann Rheum Dis; 2018 Oct; 77(10):1516-1523. PubMed ID: 29945920
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.
Merrill JT; Werth VP; Furie R; van Vollenhoven R; Dörner T; Petronijevic M; Velasco J; Majdan M; Irazoque-Palazuelos F; Weiswasser M; Korish S; Ye Y; Gaudy A; Schafer PH; Liu Z; Agafonova N; Delev N
N Engl J Med; 2022 Mar; 386(11):1034-1045. PubMed ID: 35294813
[TBL] [Abstract][Full Text] [Related]
3. Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus.
Rivellese F; Manou-Stathopoulou S; Mauro D; Goldmann K; Pyne D; Rajakariar R; Gordon P; Schafer P; Bombardieri M; Pitzalis C; Lewis MJ
Lupus Sci Med; 2021 Mar; 8(1):. PubMed ID: 33727237
[TBL] [Abstract][Full Text] [Related]
4. Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity.
Nakayama Y; Kosek J; Capone L; Hur EM; Schafer PH; Ringheim GE
J Immunol; 2017 Oct; 199(7):2388-2407. PubMed ID: 28848067
[TBL] [Abstract][Full Text] [Related]
5. Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study.
Furie RA; Hough DR; Gaudy A; Ye Y; Korish S; Delev N; Weiswasser M; Zhan X; Schafer PH; Werth VP
Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35169036
[TBL] [Abstract][Full Text] [Related]
6. Biological impact of iberdomide in patients with active systemic lupus erythematosus.
Lipsky PE; Vollenhoven RV; Dörner T; Werth VP; Merrill JT; Furie R; Petronijevic M; Velasco Zamora B; Majdan M; Irazoque-Palazuelos F; Terbrueggen R; Delev N; Weiswasser M; Korish S; Stern M; Hersey S; Ye Y; Gaudy A; Liu Z; Gagnon R; Tang S; Schafer PH
Ann Rheum Dis; 2022 Apr; 81(8):1136-42. PubMed ID: 35477518
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
[TBL] [Abstract][Full Text] [Related]
8. First-in-Human, Single- and Multiple-Ascending-Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator.
Ye Y; Gaudy A; Schafer P; Thomas M; Weiss D; Chen N; Liu L; Xue Y; Carayannopoulos L; Palmisano M
Clin Pharmacol Drug Dev; 2021 May; 10(5):471-485. PubMed ID: 32969202
[TBL] [Abstract][Full Text] [Related]
9. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
Matyskiela ME; Zhang W; Man HW; Muller G; Khambatta G; Baculi F; Hickman M; LeBrun L; Pagarigan B; Carmel G; Lu CC; Lu G; Riley M; Satoh Y; Schafer P; Daniel TO; Carmichael J; Cathers BE; Chamberlain PP
J Med Chem; 2018 Jan; 61(2):535-542. PubMed ID: 28425720
[TBL] [Abstract][Full Text] [Related]
10. [Iberdomide against Aiolos and Ikaros in systemic lupus erythematosus].
Mucke J
Z Rheumatol; 2022 Sep; 81(7):608-609. PubMed ID: 35704067
[No Abstract] [Full Text] [Related]
11. Overexpression of Aiolos in Peripheral Blood Mononuclear Cell Subsets from Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis.
Cai X; Liu X; Du S; Xu X; Liu A; Ge X; Qiao Y; Jiang Y
Biochem Genet; 2016 Feb; 54(1):73-82. PubMed ID: 26546109
[TBL] [Abstract][Full Text] [Related]
12. [Cereblon as a primary target of IMiDs].
Ito T; Handa H
Rinsho Ketsueki; 2019; 60(9):1013-1019. PubMed ID: 31597822
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects.
Gaudy A; Atsriku C; Ye Y; MacGorman K; Liu L; Xue Y; Surapaneni S; Palmisano M
Eur J Clin Pharmacol; 2021 Feb; 77(2):223-231. PubMed ID: 32965548
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation of anergy-related factors involved in regulatory T cells defects in Systemic Lupus Erythematosus patients: Rapamycin and Vitamin D efficacy in restoring regulatory T cells.
Banica LM; Besliu AN; Pistol GC; Stavaru C; Vlad V; Predeteanu D; Ionescu R; Stefanescu M; Matache C
Int J Rheum Dis; 2016 Dec; 19(12):1294-1303. PubMed ID: 25351606
[TBL] [Abstract][Full Text] [Related]
16. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
Hagner PR; Man HW; Fontanillo C; Wang M; Couto S; Breider M; Bjorklund C; Havens CG; Lu G; Rychak E; Raymon H; Narla RK; Barnes L; Khambatta G; Chiu H; Kosek J; Kang J; Amantangelo MD; Waldman M; Lopez-Girona A; Cai T; Pourdehnad M; Trotter M; Daniel TO; Schafer PH; Klippel A; Thakurta A; Chopra R; Gandhi AK
Blood; 2015 Aug; 126(6):779-89. PubMed ID: 26002965
[TBL] [Abstract][Full Text] [Related]
17. Down-regulated expression of IKZF1 mRNA in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.
Hu W; Sun L; Gao J; Li Y; Wang P; Cheng Y; Pan T; Han J; Liu Y; Lu W; Zuo X; Sheng Y; Yao S; He C; Yu Z; Yin X; Cui Y; Yang S; Zhang X
Rheumatol Int; 2011 Jun; 31(6):819-22. PubMed ID: 20680283
[TBL] [Abstract][Full Text] [Related]
18. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
[TBL] [Abstract][Full Text] [Related]
19. Lack of the transcriptional coactivator OBF-1 prevents the development of systemic lupus erythematosus-like phenotypes in Aiolos mutant mice.
Sun J; Matthias G; Mihatsch MJ; Georgopoulos K; Matthias P
J Immunol; 2003 Feb; 170(4):1699-706. PubMed ID: 12574333
[TBL] [Abstract][Full Text] [Related]
20. Protein Degradation via CRL4
Hansen JD; Condroski K; Correa M; Muller G; Man HW; Ruchelman A; Zhang W; Vocanson F; Crea T; Liu W; Lu G; Baculi F; LeBrun L; Mahmoudi A; Carmel G; Hickman M; Lu CC
J Med Chem; 2018 Jan; 61(2):492-503. PubMed ID: 28358507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
